MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Gene expression for advanced bowel cancer

Back to colon cancer blog Blogs list Cancer blog  


Subscribe To Colon Cancer Blog RSS Feed  RSS content feed What is RSS feed?

Gene expression for advanced bowel cancer




Research by researchers in France has demonstrated for the first time that identifying patterns of gene expression can be used to predict response to therapy in patients with advanced metastatic colorectal cancer.

Dr Maguy Del Rio, a scientist at the Institut de Recherche en Cancrologie de Montpellier (Montpellier, France), presented a study to the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Geneva today (Wednesday) [1] in which she and her team had identified an 11-gene signature that could be used to separate those patients who would respond to a particular chemotherapy (FOLFIRI leucovorin, fluorouracil and irinotecan) from those who would not. FOLFIRI is one of the most usually used, first-line therapys for metastatic colorectal cancer.



Gene expression for advanced bowel cancer

Dr Del Rio said: "Gene expression signatures are a new class of molecular diagnostic tests for cancer. For cancer prognosis, three tests are commercially available, all for breast cancer. It is more difficult to predict responses to anticancer drugs than it is to predict prognosis. Few studies have been made in this field. This and our prior study [2] are the first that demonstrate the utility of gene expression profiling for the prediction of response in colorectal patients".

About half of patients with colorectal cancer develop liver metastases during the course of their disease. Dr Del Rio said: "When this happens, it is critical for the success of overall therapy to chose a chemotherapy regime that is most likely to induce a maximal response during the first course of therapy. It is a major clinical challenge to identify a subset of patients who could benefit from a particular chemotherapy, and to identify those who will not and therefore need to be treated using an alternative therapy".

The scientists used microarray analysis to identify gene expression levels in samples taken from 19 colorectal cancer patients with liver metastases who had still not started chemotherapy. They followed the patients to see who responded to the chemotherapy and who did not, and, using this information, found a pattern of 11 genes that clearly separated responder and non-responder patients. They designed a mathematical model that was able to predict and classify the eight responding and 11 non-responding patients with 100% accuracy.

Dr Del Rio said: "The fact that we achieved 100% accuracy could be due to our small sample size of 19 patients. Obviously, it is essential to validate and, if necessary, to improved the gene signature in a larger independent cohort of patients. Until it is properly validated, the gene signature cannot be used in the clinic. However, in the future it could be used to identify a subset of patients would could benefit from chemotherapy and lead to an improvement in response to metastatic therapy for colorectal cancer.

"For the subset of patients who are identified as non-responders to FOLFIRI, other therapys such as FOLFOX (leucovorin, fluorouracil and oxaliplatin) chemotherapy, or newer, targeted drugs such as cetuximab and bevacizumab could be added".

At present, the test for the 11-gene signature takes about three days to run, with several steps involved: surgical removal of tumour tissue, histologic validation, RNA extraction, chip hybridization, comparative analysis of gene expression and patient's classification. The scientists hope that this process could be speeded up, but the ability to choose the correct first-line therapy is a big step forward.

"For patients with metastatic colorectal cancer, time is an important factor and to make the good first-line therapy choice could be decisive in the overall success of the therapy," said Dr Del Rio.


Posted by: Sue    Source




Did you know?
Research by researchers in France has demonstrated for the first time that identifying patterns of gene expression can be used to predict response to therapy in patients with advanced metastatic colorectal cancer. Dr Maguy Del Rio, a scientist at the Institut de Recherche en Cancrologie de Montpellier (Montpellier, France), presented a study to the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Geneva today (Wednesday) [1] in which she and her team had identified an 11-gene signature that could be used to separate those patients who would respond to a particular chemotherapy (FOLFIRI leucovorin, fluorouracil and irinotecan) from those who would not. FOLFIRI is one of the most usually used, first-line therapys for metastatic colorectal cancer.

Medicineworld.org: Gene expression for advanced bowel cancer

Main Page| Cancer blog| Cancer blogs list| Lung cancer blog| Colon cancer blog| Prostate cancer blog| Breast cancer blog| Diabetes watch blog| Heart watch blog| Allergy blog| Bladder cancer blog| Cervical cancer blog| Colon cancer news blog| Diabetes news blog| Esophageal cancer blog| Gastric cancer blog| Health news blog| Heart news blog| Infectious disease blog| Kidney watch blog| Lung disease blog| Lung cancer news blog| Mesothelioma blog| Neurology blog| Breast cancer news blog| OBGYN blog| Ophthalmology blog| Ovarian cancer blog| Cancer news blog| Pancreas cancer blog| Pediatrics blog| Prostate cancer news blog| Psychology blog| Research blog| Rheumatology blog| Society news blog| Uterine cancer blog| Weight watch blog|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.